Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
Condition: Malignant Neoplasm of Breast Interventions: Drug: Cobimetinib; Drug: Atezolizumab; Drug: Eribulin Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Not yet recruiting - verified June 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Inflammatory Breast Cancer | Study